HELX Franklin Genomic Advancements ETF
Quotazione aggiornata al Aug 27, 2026 19:59 UTC · Market data delayed approximately 15–20 minutes unless otherwise indicated.
| Chiusura precedente | 43.42 | Day Range | 43.43 – 43.71 |
| 52-Week Range | 29.80 – 43.71 | Volume | 136 |
| Avg Volume | 1.94K | AUM | $32.6M (Aug 27, 2026) |
| Expense Ratio | 0.50% | Rendimento (TTM) | 0.33% |
| NAV | 43.43 | Premio/Sconto | +0.14% indicativo |
| Inception | Feb 25, 2020 | Posizioni in portafoglio | 63 |
| Emittente | Franklin Templeton | Borsa | CBOE |
| Category | Healthcare | Indice replicato | Non indicato nei dati di fonte |
| CUSIP | 35473P520 | ISIN | US35473P5200 |
| Gestione | Non indicato nei dati di fonte | ||
About this ETF
This fund aims to generate substantial capital growth by strategically investing in a diverse array of equity securities. Its portfolio includes companies based within the United States as well as those operating in international markets, encompassing both established and emerging economies. The core investment thesis of the fund centers on companies engaged in genomic advancements. Specifically, it seeks out firms that the investment manager believes are fundamentally dedicated to, or are poised to significantly benefit from, efforts to prolong and enhance the overall quality of life for both humans and animals. This is accomplished by integrating cutting-edge technological and scientific innovations, improvements, and breakthroughs in the field of genomics directly into their business models and operations.
Description from the fund data provider · profilo aggiornato al Aug 27, 2026.
Grafico del prezzo
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Fonte: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Rendimento del prezzo | +11.74% | +25.11% | +25.87% | +19.59% | +46.11% | +12.93% | -4.95% | — | +9.59% |
| Rendimento totale | +11.73% | +25.09% | +25.86% | +19.58% | +46.64% | +13.06% | -4.83% | — | +9.71% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance al Aug 26, 2026. Le performance passate non garantiscono risultati futuri.
Fees
| Expense ratio netto | 0.50% | Annual cost of a $10,000 investment | $50.00 |
Calcolo a solo scopo illustrativo: expense ratio × 10.000 $. Esclude i costi di negoziazione, gli spread denaro/lettera, le imposte e le variazioni del valore dell'investimento. I dettagli sull'expense ratio lordo e netto e le eventuali esenzioni dalle commissioni sono riportati nel prospetto.
Posizioni in portafoglio
Posizioni in portafoglio al Aug 22, 2026 — data di riferimento del portafoglio fornita dal provider di dati; le posizioni non sono in tempo reale. 70 righe nel database.
| # | Posizione | Ticker | Peso | Azioni | Valore di Mercato |
|---|---|---|---|---|---|
| 1 | GUARDANT HEALTH INC | GH | 9.55% | 18.14K | $3.0M |
| 2 | NATERA INC | NTRA | 8.39% | 8.23K | $2.7M |
| 3 | KRYSTAL BIOTECH INC | KRYS | 5.39% | 5.10K | $1.7M |
| 4 | ADAPTIVE BIOTECHNOLOGIES | ADPT | 4.44% | 55.67K | $1.4M |
| 5 | LIGAND PHARMACEUTICALS | LGND | 3.95% | 4.38K | $1.3M |
| 6 | TWIST BIOSCIENCE CORP | TWST | 3.88% | 9.07K | $1.2M |
| 7 | BRIDGEBIO PHARMA INC | BBIO | 3.66% | 14.07K | $1.2M |
| 8 | UNITED THERAPEUTICS CORP | UTHR | 3.17% | 1.94K | $1.0M |
| 9 | ELI LILLY & CO | LLY | 2.98% | 762 | $948.2K |
| 10 | TRAVERE THERAPEUTICS INC | TVTX | 2.93% | 14.49K | $933.8K |
| 11 | VERTEX PHARMACEUTICALS IN | VRTX | 2.81% | 1.66K | $894.1K |
| 12 | SAMSUNG BIOLOGICS CO LTD | 207940.KS | 2.67% | 752 | $849.9K |
| 13 | CORTEVA INC | CTVA | 2.44% | 9.80K | $778.7K |
| 14 | MEDPACE HOLDINGS INC | MEDP | 2.33% | 1.21K | $743.1K |
| 15 | REGENERON PHARMACEUTICALS | REGN | 2.24% | 862 | $712.6K |
| 16 | ASTRAZENECA PLC | AZN.L | 2.20% | 4.26K | $701.2K |
| 17 | TEMPUS AI INC-CL A | TEM | 1.84% | 8.77K | $584.8K |
| 18 | ARGENX SE | ARGX.BR | 1.72% | 529 | $547.1K |
| 19 | REPLIGEN CORP | RGEN | 1.61% | 2.84K | $511.5K |
| 20 | NEUROCRINE BIOSCIENCES IN | NBIX | 1.57% | 3.28K | $501.0K |
| 21 | CHARLES RIVER LABORATORIE | CRL | 1.52% | 1.67K | $485.8K |
| 22 | BIONTECH SE-ADR | BNTX | 1.37% | 3.93K | $435.5K |
| 23 | PRAXIS PRECISION MEDICINE | PRAX | 1.31% | 1.15K | $418.2K |
| 24 | CAREDX INC | CDNA | 1.26% | 8.57K | $402.8K |
| 25 | VERACYTE INC | VCYT | 1.22% | 9.34K | $390.3K |
| 26 | STOKE THERAPEUTICS INC | STOK | 1.20% | 12.16K | $381.8K |
| 27 | PTC THERAPEUTICS INC | PTCT | 1.19% | 5.37K | $378.4K |
| 28 | GRAIL INC | GRAL | 1.17% | 4.77K | $372.2K |
| 29 | JAZZ PHARMACEUTICALS PLC | JAZZ | 1.08% | 1.39K | $345.4K |
| 30 | INSMED INC | INSM | 1.07% | 2.73K | $341.2K |
| 31 | IQVIA HOLDINGS INC | IQV | 1.04% | 1.29K | $330.3K |
| 32 | REVOLUTION MEDICINES INC | RVMD | 1.03% | 1.54K | $326.9K |
| 33 | CRISPR THERAPEUTICS AG | CRSP | 0.98% | 5.39K | $313.2K |
| 34 | THERMO FISHER SCIENTIFIC | TMO | 0.89% | 451 | $283.0K |
| 35 | SARTORIUS AG-VORZUG | SRT3.DE | 0.88% | 969 | $281.8K |
| 36 | ANAPTYSBIO INC | ANAB | 0.82% | 4.60K | $260.5K |
| 37 | CADENCE DESIGN SYS INC | CDNS | 0.76% | 776 | $243.3K |
| 38 | BEAM THERAPEUTICS INC | BEAM | 0.72% | 8.12K | $230.5K |
| 39 | HINGE HEALTH INC-A | HNGE | 0.68% | 2.52K | $215.4K |
| 40 | FIRST TRACKS BIOTHERAPEUT | TRAX | 0.66% | 5.04K | $211.4K |
| 41 | AXSOME THERAPEUTICS INC | AXSM | 0.65% | 1.00K | $208.4K |
| 42 | AGILENT TECHNOLOGIES INC | A | 0.64% | 1.31K | $204.8K |
| 43 | DANAHER CORP | DHR | 0.61% | 902 | $194.8K |
| 44 | GENMAB A/S -SP ADR | GMAB | 0.54% | 5.12K | $171.1K |
| 45 | QIAGEN N.V. | QIA.DE | 0.52% | 3.66K | $164.5K |
| 46 | ROIVANT SCIENCES LTD | ROIV | 0.48% | 4.13K | $152.3K |
| 47 | CELCUITY INC | CELC | 0.46% | 1.62K | $147.0K |
| 48 | MINERALYS THERAPEUTICS IN | MLYS | 0.44% | 5.44K | $140.2K |
| 49 | MODERNA INC | MRNA | 0.44% | 1.05K | $139.7K |
| 50 | VERADERMICS INC | MANE | 0.42% | 1.27K | $133.9K |
| 51 | COGENT BIOSCIENCES INC | COGT | 0.41% | 3.67K | $129.6K |
| 52 | KINIKSA PHARMACEUTICALS I | KNSA | 0.39% | 1.58K | $124.3K |
| 53 | RHYTHM PHARMACEUTICALS IN | RYTM | 0.38% | 1.12K | $122.2K |
| 54 | ARCUTIS BIOTHERAPEUTICS I | ARQT | 0.38% | 4.74K | $120.1K |
| 55 | BRISTOL-MYERS SQUIBB CO | BMY | 0.36% | 1.73K | $113.4K |
| 56 | BIO-RAD LABORATORIES-A | BIO | 0.31% | 260 | $97.9K |
| 57 | BEONE MEDICINES LTD-ADR | ONC | 0.28% | 241 | $89.0K |
| 58 | TARSUS PHARMACEUTICALS IN | TARS | 0.27% | 1.22K | $87.0K |
| 59 | NEUROGENE INC | NGNE | 0.25% | 2.12K | $80.6K |
| 60 | ULTRAGENYX PHARMACEUTICAL | RARE | 0.24% | 2.97K | $75.2K |
| 61 | TG THERAPEUTICS INC | TGTX | 0.21% | 1.34K | $67.9K |
| 62 | LIQUIDIA CORP | LQDA | 0.21% | 933 | $66.3K |
| 63 | GENEDX HOLDINGS CORP | WGS | 0.16% | 616 | $50.9K |
| 64 | SAMSUNG EPISHOLDINGS CO L | 0126Z0.KS | 0.15% | 174 | $47.4K |
| 65 | ALNYLAM PHARMACEUTICALS I | ALNY | 0.10% | 143 | $32.8K |
| 66 | IONIS PHARMACEUTICALS INC | IONS | 0.10% | 552 | $32.4K |
| 67 | CASH | — | 0.00% | 1.50K | $1.5K |
| 68 | OMNIAB INC - 12.5 EARNOUT | 2200963 | 0.00% | 240 | $0.00 |
| 69 | OMNIAB INC - 15.00 EARNOU | 2200964 | 0.00% | 240 | $0.00 |
| 70 | Net Current Assets | — | -0.01% | 0 | -$2.1K |
Click a ticker to see every ETF that owns it.
Esposizione settoriale
Esposizione Geografica
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: Nessuna copertura valutaria indicata nel nome del fondo.
Distributions
| Rendimento (TTM) | 0.33% | Distribuito (ultimi 12 mesi) | $0.1433 |
| Frequenza | Irregular | Rendimento SEC | Non fornito dalla nostra fonte dati — consulta la pagina dell'emittente |
| Ultima ex-data | Dec 30, 2025 | Ultimo pagamento | $0.1433 (Jan 08, 2026) |
| Crescita 1A | — | Crescita 3A / 5A (ann.) | — / — |
| Ex-date | Record | Data di pagamento | Importo |
|---|---|---|---|
| Dec 30, 2025 | Dec 30, 2025 | Jan 08, 2026 | $0.1433 |
| Dec 30, 2021 | Dec 31, 2021 | Jan 07, 2022 | $0.0040 |
| Dec 13, 2021 | Dec 14, 2021 | Dec 21, 2021 | $0.1140 |
| Dec 14, 2020 | Dec 15, 2020 | Dec 23, 2020 | $0.0520 |
Rendimento da distribuzione trailing = ultimi 12 mesi di liquidità distribuita ÷ prezzo corrente. NON corrisponde al rendimento SEC a 30 giorni e la continuità delle distribuzioni non è garantita. La differenza spiegata →
Statistiche di rischio
| Volatilità 1A / 3A | 22.83% / 21.73% | Sharpe 1A / 3A | 2.06 / 0.559 |
| Drawdown massimo 1A / 3A | -18.00% / -29.48% | Sortino 1A | 3.31 |
| Beta vs S&P 500 (3Y) | 0.935 | Correlation vs S&P 500 (1Y) | 0.512 |
| Downside deviation 1Y | 14.21% | Tasso privo di rischio utilizzato | 3.71% (3M T-bill, FRED) |
Computed by ETF Explorer da chiusure giornaliere rettificate per i dividendi; volatilità e drawdown sono valori annualizzati/di periodo; l'esposizione all'S&P 500 è approssimata tramite SPY. Aggiornato al Aug 27, 2026. Formule →
Liquidità
| Volume odierno | 136 | Average volume | 1.94K |
| AUM | $32.6M | Premio/Sconto | +0.14% |
| Bid/Ask spread | Non fornito dalla nostra fonte dati. Verifica lo spread sul tuo broker; gli spread sono più ampi in apertura e in chiusura. | ||
Il premio/sconto confronta il prezzo di mercato in ritardo con l'ultimo NAV comunicato — un dato indicativo, non il premio/sconto ufficiale di chiusura. Come funziona la liquidità degli ETF →
Flussi del Fondo (stimati)
| Periodo | Est. net flow | % of starting AUM | AUM start → end |
|---|---|---|---|
| 1 Day | $640.0K | +2.00% | $31.9M → $32.6M |
| 1 Week | $1.1M | +3.53% | $30.8M → $32.6M |
ETF Explorer estimate: change in reported AUM minus the market-move effect, from our own daily snapshots. Not official issuer creation/redemption data.
Risorse ufficiali del fondo
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source — review them before investing.
Ultime Notizie su HELX
Nessun articolo menziona direttamente questo fondo negli ultimi 7 giorni — viene mostrata la copertura generale sugli ETF.
Guida rapida: l'AUM è la dimensione del fondo. L'expense ratio è il costo annuo incorporato nei rendimenti. Il NAV è il valore di ciò che il fondo detiene per quota; il prezzo di mercato può essere leggermente superiore (premio) o inferiore (sconto) al NAV. Il rendimento totale presuppone il reinvestimento delle distribuzioni. Ogni dato riporta la propria data di aggiornamento, poiché portafoglio, patrimonio e quotazioni si aggiornano con frequenze diverse.